Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
University of Alabama at Birmingham
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
AstraZeneca
Institut du Cancer de Montpellier - Val d'Aurelle
PinkDx, Inc.
National Institutes of Health Clinical Center (CC)
AstraZeneca
Genmab
Imperial College London
Northwestern University
Northwestern University
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Atavistik Bio, Inc
Centre Oscar Lambret
Abramson Cancer Center at Penn Medicine
Pfizer
M.D. Anderson Cancer Center
Duke University
Dana-Farber Cancer Institute
University of Miami
University of Tennessee Graduate School of Medicine
Asan Medical Center
Queensland Centre for Gynaecological Cancer
DL Analytics
Natera, Inc.
Dana-Farber Cancer Institute
University of Alabama at Birmingham
Rutgers, The State University of New Jersey
University of Kentucky
National Institutes of Health Clinical Center (CC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Seagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yuri Semenyuk Rivne Regional Clinical Hospital
Washington University School of Medicine
City of Hope Medical Center
University Health Network, Toronto
Assiut University
Icahn School of Medicine at Mount Sinai
University Health Network, Toronto
Shasqi, Inc.
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Stanford University
University of Virginia
M.D. Anderson Cancer Center
University of California, San Diego
Bakirkoy Dr. Sadi Konuk Research and Training Hospital